$PULM
Pulmatrix, Inc.

2022 Q4 Form 10-Q Financial Statement

#000149315222031256 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q4
Revenue $1.708M $1.872M $456.0K
YoY Change 274.56% 75.12% -77.2%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.566M $1.685M $1.540M
YoY Change 1.69% 1.75% 9.22%
% of Gross Profit
Research & Development $4.467M $5.287M $2.959M
YoY Change 50.96% 31.32% -9.51%
% of Gross Profit
Depreciation & Amortization $39.00K $41.00K $35.00K
YoY Change 11.43% -10.87% -41.67%
% of Gross Profit
Operating Expenses $6.033M $6.972M $4.499M
YoY Change 34.1% 22.7% -3.66%
Operating Profit -$5.100M
YoY Change -37.73%
Interest Expense $191.0K $102.0K $1.000K
YoY Change 19000.0% 10100.0%
% of Operating Profit
Other Income/Expense, Net -$82.00K $48.00K $11.00K
YoY Change -845.45% 860.0% -104.78%
Pretax Income -$4.216M -$5.052M -$4.031M
YoY Change 4.59% -38.27% 39.0%
Income Tax
% Of Pretax Income
Net Earnings -$4.216M -$5.052M -$4.031M
YoY Change 4.59% -38.27% 39.0%
Net Earnings / Revenue -246.84% -269.87% -883.99%
Basic Earnings Per Share -$1.45
Diluted Earnings Per Share -$1.16 -$1.452M -$1.404M
COMMON SHARES
Basic Shares Outstanding 3.639M shares 3.478M shares
Diluted Shares Outstanding 3.478B shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $35.63M $40.68M $53.84M
YoY Change -33.83% -23.94% 70.06%
Cash & Equivalents $35.63M $40.68M $53.84M
Short-Term Investments
Other Short-Term Assets $1.221M $2.066M $871.0K
YoY Change 40.18% 120.26% 10.25%
Inventory
Prepaid Expenses
Receivables $1.298M $476.0K $67.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $38.15M $43.23M $54.78M
YoY Change -30.36% -20.6% 68.34%
LONG-TERM ASSETS
Property, Plant & Equipment $235.0K $265.0K $2.414M
YoY Change -90.27% -76.04% 30.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $389.0K $428.0K $1.625M
YoY Change -76.06% 109.8% 712.5%
Total Long-Term Assets $2.806M $3.225M $4.039M
YoY Change -30.53% 146.18% -28.26%
TOTAL ASSETS
Total Short-Term Assets $38.15M $43.23M $54.78M
Total Long-Term Assets $2.806M $3.225M $4.039M
Total Assets $40.95M $46.45M $58.82M
YoY Change -30.37% -16.68% 54.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.188M $1.155M $839.0K
YoY Change 41.6% 32.0% -9.78%
Accrued Expenses $2.495M $2.748M $2.664M
YoY Change -6.34% 20.37% -15.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.022M $6.324M $4.442M
YoY Change 13.06% 23.23% -46.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.822M $5.080M $6.926M
YoY Change -30.38% -6.32% 2.15%
Total Long-Term Liabilities $4.822M $5.080M $6.926M
YoY Change -30.38% -6.32% 2.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.022M $6.324M $4.442M
Total Long-Term Liabilities $4.822M $5.080M $6.926M
Total Liabilities $9.844M $11.40M $11.37M
YoY Change -13.41% 8.04% -24.36%
SHAREHOLDERS EQUITY
Retained Earnings -$273.5M -$269.3M -$254.6M
YoY Change 7.4%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $31.11M $35.05M $47.45M
YoY Change
Total Liabilities & Shareholders Equity $40.95M $46.45M $58.82M
YoY Change -30.37% -16.68% 54.09%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q4
OPERATING ACTIVITIES
Net Income -$4.216M -$5.052M -$4.031M
YoY Change 4.59% -38.27% 39.0%
Depreciation, Depletion And Amortization $39.00K $41.00K $35.00K
YoY Change 11.43% -10.87% -41.67%
Cash From Operating Activities -$5.046M -$3.604M -$4.396M
YoY Change 14.79% 8.82% 59.28%
INVESTING ACTIVITIES
Capital Expenditures $9.000K $0.00 -$26.00K
YoY Change -134.62% -100.0% -67.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$9.000K $0.00 -$26.00K
YoY Change -65.38% -100.0% -67.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 1.382M 6.192M
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -5.046M -3.604M -4.396M
Cash From Investing Activities -9.000K 0.000 -26.00K
Cash From Financing Activities 0.000 1.382M 6.192M
Net Change In Cash -5.055M -2.222M 1.770M
YoY Change -385.59% -34.88% -162.32%
FREE CASH FLOW
Cash From Operating Activities -$5.046M -$3.604M -$4.396M
Capital Expenditures $9.000K $0.00 -$26.00K
Free Cash Flow -$5.055M -$3.604M -$4.370M
YoY Change 15.68% 12.2% 63.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Central Index Key
EntityCentralIndexKey
0001574235
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
usd
CY2022Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2022Q1 PULM Stock Issued During Period Value Adjustment Due To Reverse Stock Split
StockIssuedDuringPeriodValueAdjustmentDueToReverseStockSplit
usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
usd
us-gaap Payments For Repurchase Of Preferred Stock And Preference Stock
PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
usd
CY2021Q4 PULM Prepaid Software And Hosting Costs
PrepaidSoftwareAndHostingCosts
usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Entity File Number
EntityFileNumber
001-36199
dei Entity Registrant Name
EntityRegistrantName
PULMATRIX, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-1821392
dei Entity Address Address Line1
EntityAddressAddressLine1
99 Hayden Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 390
dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
357-2333
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
PULM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3639185 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40683000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
67000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53840000 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
153000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
476000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1913000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
871000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
43225000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
54778000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
265000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
321000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1060000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2093000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1472000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1625000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
428000 usd
CY2022Q3 us-gaap Assets
Assets
46450000 usd
CY2021Q4 us-gaap Assets
Assets
58817000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1155000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
839000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2748000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1233000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1281000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1431000 usd
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1140000 usd
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
939000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6324000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4442000 usd
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5080000 usd
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
6069000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
857000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
11404000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
11368000 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
1081000 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3639185 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3639185 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3222037 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3222037 shares
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-22000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
304306000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
301008000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-269260000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-254640000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
35046000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
47449000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46450000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58817000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1872000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1069000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4363000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4713000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5287000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4026000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13773000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12423000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1685000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1656000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5212000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4837000 usd
CY2021Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3577000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3577000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
6972000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
9259000 usd
us-gaap Operating Expenses
OperatingExpenses
18985000 usd
us-gaap Operating Expenses
OperatingExpenses
20837000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5100000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8190000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-14622000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-16124000 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
102000 usd
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
118000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
6000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-54000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-116000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
48000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5052000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-8184000 usd
us-gaap Net Income Loss
NetIncomeLoss
-14620000 usd
us-gaap Net Income Loss
NetIncomeLoss
-16140000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.45
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.91
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.08
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3478157 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2812454 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3383171 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2654099 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
47449000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
281000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4973000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
42757000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
277000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4595000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
38439000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1382000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
277000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5052000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
35046000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
23139000 usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37079000 usd
CY2021Q1 PULM Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
204000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
328000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4104000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
56646000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
299000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3852000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
53093000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
53093000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
284000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-8184000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
45193000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
45193000 usd
us-gaap Net Income Loss
NetIncomeLoss
-14620000 usd
us-gaap Net Income Loss
NetIncomeLoss
-16140000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
123000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
134000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1033000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
728000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
835000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
911000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3577000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
409000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-75000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1042000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
141000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
428000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
478000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-50000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1515000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-643000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1007000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-845000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-788000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2937000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14310000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15331000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
77000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
118000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-77000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-118000 usd
us-gaap Payments For Repurchase Of Preferred Stock And Preference Stock
PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
152000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1382000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37079000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
204000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1230000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37283000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13157000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
21834000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55465000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31861000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42308000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
53695000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40683000 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53491000 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
153000 usd
CY2022Q3 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
1472000 usd
CY2021Q3 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
204000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42308000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53695000 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1081000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2961000 usd
CY2022Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-20 reverse stock split
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84D_eus-gaap--UseOfEstimates_zur4gXzpfGF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zGp5NAJywk12">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. The most significant estimates and assumptions in the Company’s condensed consolidated financial statements include, but are not limited to, estimates of future expected costs in order to derive and recognize revenue, estimates related to clinical trial accruals and upfront deposits, fair value used to record preferred stock and warrant transactions, incremental borrowing rate, and accounting for income taxes and the related valuation allowance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zfNVWtXDk0mh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zMJf78Ue8Mu2">Concentrations of Credit Risk and Off-Balance Sheet Arrangements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash is a financial instrument that potentially subjects the Company to concentrations of credit risk. For all periods presented, substantially all of the Company’s cash was deposited in an account at a single financial institution that management believes is creditworthy. The Company is exposed to credit risk in the event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. The Company maintains its cash at a high-quality financial institution and has not incurred any losses to date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine months ended September 30, 2022, one customer accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zXMbgdBPvD2l">99% </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of revenue recognized in the accompanying financial statements. For the nine months ended September 30, 2021, two customers accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_z9CrfSAGVQy">99% </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of revenue recognized in the accompanying financial statements. As of September 30, 2022, one customer accounted for <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zQkDt0aiPVsl">99% </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of accounts receivable recorded in the accompanying financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2750000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2640000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
265000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
321000 usd
CY2022Q3 PULM Prepaid Clinical And Consulting
PrepaidClinicalAndConsulting
1239000 usd
CY2021Q4 PULM Prepaid Clinical And Consulting
PrepaidClinicalAndConsulting
230000 usd
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
428000 usd
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
325000 usd
CY2022Q3 PULM Prepaid Software And Hosting Costs
PrepaidSoftwareAndHostingCosts
140000 usd
CY2022Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
106000 usd
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
316000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1913000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
871000 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3015000 usd
CY2022Q3 PULM Transaction Costs
TransactionCosts
22000000.0 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
The Series A Preferred Stock does not have any mandatory redemption provisions, contingently redeemable redemption provisions, preferential dividend rights, liquidation preferences, or voting rights, apart from mirrored, non-discretionary voting rights with common stock as a single class, equal to 100,000 votes per share of common stock underlying the Series A Preferred Stock on the Reverse Stock Split proposal which was approved by the Company’s stockholders at a special stockholder meeting on February 10, 2022
us-gaap Depreciation And Amortization
DepreciationAndAmortization
123000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
134000 usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1506000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
97000 usd
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
960000 usd
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1051000 usd
CY2022Q3 PULM Accrued Legal And Patent Current
AccruedLegalAndPatentCurrent
126000 usd
CY2021Q4 PULM Accrued Legal And Patent Current
AccruedLegalAndPatentCurrent
58000 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
156000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
27000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2748000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1233000 usd
PULM Agreement Description
AgreementDescription
The Company and Cipla will each be responsible for 60% and 40%, respectively, of the Company’s overhead costs and the time spent by the Company’s employees and consultants on development of the Product (“Direct Costs”), in addition to which, Cipla will reimburse the Company an amount equal to 10% of aggregate Direct Costs upon the achievement of certain development milestones set forth in the table below, potentially bringing the sharing of Direct Costs to a 50/50 basis. The Company will continue to share all other development costs with Cipla that are not Direct Costs, such as the cost of clinical research organizations, manufacturing costs and other third-party costs, on a 50/50 basis
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
PULM Warrants Expired Shares
WarrantsExpiredShares
254942 shares
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
277000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
284000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
835000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
911000 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
4400000 usd
us-gaap Reimbursement From Limited Partnership Investment
ReimbursementFromLimitedPartnershipInvestment
1900000 usd
CY2022Q3 us-gaap Other Commitment
OtherCommitment
4400000 usd
CY2022Q3 us-gaap Other Commitment Due In Next Twelve Months
OtherCommitmentDueInNextTwelveMonths
4000000.0 usd
CY2022Q3 us-gaap Other Commitment Due After Fifth Year
OtherCommitmentDueAfterFifthYear
400000 usd
CY2022Q3 us-gaap Area Of Land
AreaOfLand
22000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
357000 usd
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
259000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1072000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
777000 usd
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
206000 usd
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
97000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
556000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
319000 usd
CY2022Q3 us-gaap Lease Cost
LeaseCost
563000 usd
CY2021Q3 us-gaap Lease Cost
LeaseCost
356000 usd
us-gaap Lease Cost
LeaseCost
1628000 usd
us-gaap Lease Cost
LeaseCost
1096000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
7000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
11000 usd
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
431000 usd
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
299000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1046000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
896000 usd
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y8M12D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.030 pure
CY2022Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
431000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
863000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1294000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
13000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1281000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1281000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1281000 usd
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1592721000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1592721000 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1416435000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1416435000 shares

Files In Submission

Name View Source Status
pulm-20220930_lab.xml Edgar Link unprocessable
0001493152-22-031256-index-headers.html Edgar Link pending
0001493152-22-031256-index.html Edgar Link pending
0001493152-22-031256.txt Edgar Link pending
0001493152-22-031256-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
pulm-20220930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
pulm-20220930_pre.xml Edgar Link unprocessable
pulm-20220930_cal.xml Edgar Link unprocessable
pulm-20220930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending